Glaukos has filed a registration statement with the U.S. Securities and Exchange Commission concerning a proposed initial public offering of its common stock, the company announced in a press release.
The number of shares to be offered and the price range for the proposed offering have not been determined, the release said. In addition, the company has applied to list its common stock on the New York Stock Exchange under the trading symbol “GKOS.”
“A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective,” the release said.
According to the release, J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co. are serving as joint book-running managers for the offering. William Blair and Cantor Fitzgerald & Co. are acting as co-managers.
Glaukos manufactures the iStent trabecular micro-bypass stent, which was approved by the FDA in June 2012. The company is also developing the iStent inject and the iStent supra.